Yuki Gosei Kogyo Co., Ltd.
4531・Standard Market・Chemicals
Business
Yuki Gosei Yakuhin Kogyo (Organic Synthesis Chemical Industry) was founded in 1947 as a specialized fine chemicals manufacturer, with its Joban Plant in Ibaraki Prefecture serving as its main production base. The company operates in three segments: Amino Acids (glycine, etc.), Chemical Products (raw materials for tire cord adhesives, agrochemical intermediates, silicone compounds, etc.), and Pharmaceuticals (including contract manufacturing of active pharmaceutical ingredients and intermediates), with domestic and overseas chemical, pharmaceutical, and food manufacturers as its main customers. Net sales for FY2026 (ending March 2026) reached ¥15,448 million, marking a record high for the seventh consecutive fiscal period. The export ratio reached 51.9%, and the company maintains a global sales network centered on Asia, Europe, and North America. The company is listed on the Standard Market of the Tokyo Stock Exchange.
Business Model
The company primarily adopts a make-to-stock production system, manufacturing and selling Amino Acids, Chemical Products, and Pharmaceuticals products at the Joban Plant. Sales concentration to the top 10 major customers is high at 68.8% (FY2026 (ending March 2026)), with ongoing transactions with companies such as Nagase & Co. and Chugai Pharmaceutical supporting the revenue base. In the pharmaceuticals field, the company also operates a CDMO (Contract Development and Manufacturing Organization) business, aiming to diversify value-added revenue. Fundraising combines operating cash flow with borrowings from financial institutions.
Company Strengths
Revenue for FY2026 (ending March 2026) reached ¥15,448 million, marking a record high for the 7th consecutive fiscal period. Revenue has grown approximately 25% over four years from ¥12,361 million in FY2022 (ended March 2022), with diversified product offerings across the three segments of Amino Acids, Chemical Products, and Pharmaceuticals supporting stable sales growth.
Export sales for FY2026 (ending March 2026) totaled ¥8,018 million (export ratio of 51.9%), continuing to rise from 49.8% in the previous period. Regional diversification has been achieved, with Asia accounting for ¥3,806 million (47.5%), Europe for ¥2,490 million (31.1%), and North America for ¥1,682 million (21.0%), building a sales structure resilient to fluctuations in domestic demand.
In June 2025, new glycine production expansion equipment was installed at the Joban Plant, with a national government subsidy of ¥1,854 million received and accounted for under the deferred income (compressed entry) method. The company has a track record of enhancing production capacity through capital investment leveraging government subsidies while limiting its own financial burden. R&D expenses of ¥618 million were also invested, promoting continuous technological development across the three fields of Amino Acids, Chemical Products, and Pharmaceuticals.
ENVALITH's Perspective
Performance Trend
Revenue increased 25% over five periods, from ¥12,361 million in FY2022 to ¥15,448 million in FY2026, marking a record high for the 7th consecutive period. However, operating profit fell sharply by 68.4%, from ¥1,216 million in FY2025 to ¥383 million in FY2026, and net income attributable to owners of parent also dropped 65.1%, from ¥896 million to ¥313 million. The main causes were: (1) a rapid decline in market prices and share for certain electronic material-related products within Chemical Products (affected by an external factor—the easing of supply-demand conditions for general-purpose products due to the slowdown in the Chinese economy); (2) the first-year depreciation burden from the Amino Acids facility completed in June 2025 (depreciation expense of ¥1,238 million); and (3) an increase in interest expenses from ¥75 million to ¥143 million. The cost of sales ratio rose from 78.1% to 83.0%, and gross profit decreased from ¥3,307 million to ¥2,620 million. For FY2027 (ending March 2027), the company forecasts revenue of ¥16,000 million, but the profit forecast remains undetermined due to the impact of the situation in the Middle East.
Growth Strategy
Expansion of amino acid production capacity, growth in chemical products, expansion of pharmaceutical contract manufacturing, and promotion of profit structure reform
The Amino Acids facility completed in June 2025 (national subsidy of ¥1,854 million received, with deferral accounting applied) began operating from FY2026 (ending March 2026). Sales for pharmaceutical applications remained strong, but due to a decline in food additive applications, Amino Acids sales for FY2026 (ending March 2026) were nearly flat at ¥5,156 million. Improving production efficiency through stabilized facility operation and concentrating on pharmaceutical applications will be key to future earnings contribution.
Chemical Products sales increased to ¥5,629 million (up ¥532 million, +10.5% year on year) driven by strong sales of raw materials for polymer materials and tire cord adhesives. However, market prices and share for some electronic materials products declined rapidly, significantly worsening profitability in the fourth quarter. The company has stated that profitability improvement is still ongoing in FY2027 (ending March 2027), making an accelerated shift to high value-added products an urgent priority.
In response to risks of procurement delays and price surges for raw materials and fuel amid escalating tensions in the Middle East, the company is promoting a fundamental reform of its profit structure, including supply chain strengthening initiatives begun last fiscal year. Thorough cost reductions and cuts to selling, general and administrative expenses are also being implemented in parallel. With the profit forecast for FY2027 (ending March 2027) undetermined, the effectiveness of this reform is a precondition for earnings recovery.
Last updated: July 19, 2026